Company Overview and News

9
Sears, Exelixis Drop into Monday’s 52-Week Low Club

2018-10-15 247wallst - 1
October 15, 2018: Here are four stocks trading with heavy volume among 212 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 1.57 to 1, and on the Nasdaq, advancers led decliners by about 1.25 to 1.
SHLD EXEL LPI SHLDW WY

3
AVEO Pharmaceuticals Enters A Critical Juncture Amid Stock Market Uncertainty. Will Its TKI-That-Could Prevail?

2018-10-12 seekingalpha
Expansions of reimbursement and hope for approval in the US are important catalysts for the company in the near term.
EXEL AVEO BMY

 
EXEL / Exelixis, Inc. / BlackRock Inc. - null (Passive Investment)

2018-10-10 sec.gov
us30161q1040_100818.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) EXELIXIS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 30161Q104 -------------------------------------------------------- (CUSIP Number) September 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page
EXEL

 
EXEL / Exelixis, Inc. / BlackRock Inc. - null (Passive Investment)

2018-10-10 sec.gov
us30161q1040_100818.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) EXELIXIS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 30161Q104 -------------------------------------------------------- (CUSIP Number) September 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page
EXEL

1
Exelixis Initiates Key Late-Stage Cancer Trial

2018-10-08 247wallst - 1
Exelixis Inc. (NASDAQ: EXEL) shares dipped on Monday after the company announced that it has initiated a late-stage trial in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
EXEL

 
Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL)

2018-10-08 zacks
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Exelixis (EXEL - Free Report) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.
EXEL

62
8 Stocks to Buy That Are Growing Faster Than Amazon

2018-10-03 investorplace - 3
Do you think Amazon.com (NASDAQ:AMZN) is a growth machine like no other, one of the best stocks to buy? It’s a beast to be sure, with the most recently reported quarterly top line up a healthy 22% … a pace that’s pretty much been the norm for a while now. Profits are growing nicely as well, as its AWS (Amazon Web Services) division — the company’s fastest-growing segment — produces high-margin revenue.
JD FB BABA EXEL AMZN DATA CTRP YELP ABMD SBGI CRM

1
Exelixis, Inc. (EXEL) Presents at Cantor Fitzgerald Global Healthcare Conference Call (Transcript)

2018-10-02 seekingalpha - 1
Hi. I’m Alethia Young. I’m one of the large and small midcap biotech analysts here at Cantor. I’m very happy to have Exelixis; Michael Morrissey who’s the President and CEO and Chris Senner who is the CFO. What we’re going to do is there’s a breakout after this so I will figure out what room that’s in and let everyone know in the room. But I’m going to let Michael make some introductory comments and then we’ll be doing a fireside chat.
EXEL

1
Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx

2018-09-24 zacks - 1
Exelixis, Inc. (EXEL - Free Report) and partner Ipsen Biopharmaceuticals received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for the label expansion of Cabometyx (cabozantinib) tablets. The company is seeking approval for Cabometyx tablets as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults, who have been previously treated with Bayer’s (BAYRY - Free Report) Nexavar (sorafenib).
EXEL GILD LGNZZ LGND RDN LGNYZ LGNXZ LGNDZ

9
Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada

2018-09-20 zacks - 1
Exelixis, Inc. (EXEL - Free Report) along with its partner Ipsen Biopharmaceuticals Canada announced that Health Canada has approved Cabometyx (cabozantinib) tablets for the treatment of advanced renal cell carcinoma (RCC) in adult patients, previously treated with vascular endothelial growth factor targeted therapy.
WFC WFCNP EXEL GILD RHT NVS CSIQ

53
7 Biotech Stocks to Buy Now

2018-09-19 investorplace - 14
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
NKTR OPK EXEL CELGZ GERN JNJ CELG FOLD ALNY

14
JD.com, Exelixis Stumble into Monday’s 52-Week Low Club

2018-09-17 247wallst - 2
September 17, 2018: Here are four stocks trading with heavy volume among 107 equities making new 52-week lows in Monday’s session. On the NYSE decliners led advancers by about 1.6 to 1, and on the Nasdaq, decliners led advancers by about 1.94 to 1.
JD TRQ EXEL FND TRQ

2
Exelixis: An Updated View

2018-09-14 seekingalpha - 2
After a massive rally over the previous 18 months, the shares have dropped some 40% so far in 2018.
EXEL

1
Invesco, Chemours Slide into Thursday’s 52-Week Low Club

2018-09-13 247wallst
September 13, 2018: Here are four stocks trading with heavy volume among 102 equities making new 52-week lows in Thursday’s session. On the NYSE advancers led decliners by about 1.25 to 1, and on the Nasdaq, advancers led decliners by about 1.08 to 1.
EXEL XRS TAL CC IVZ

2
Your Cancer Highlight: A Pfizer-Merck KGaA Collab Bears Fruit In The Competitive Kidney Cancer Market

2018-09-13 seekingalpha - 1
The renal cell cancer space has been highly competitive, with substantial disruption coming in just the past few years.
MKGAF EXEL MKGAY PFE

EXEL: Exelixis Analysis and Research Report

2018-02-15 - Asif

Exelixis is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX® (cabozantinib) tablets approved for previously treated advanced renal cell carcinoma, or RCC, and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC® (cobimetinib) tablets, is a reversible inhibitor of MEK, marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EXEL / Exelixis, Inc. on message board site Silicon Investor.

Exelixis, Inc. (EXEL) Exelixis, Inc. (EXEL) Exelixis, Inc. (EXEL) PRXL - Parexel International PRXL - Parexel International PRXL - Parexel International
NEXELL THE FASTEST GROWTH IN BIOTECHS NEXL NEXELL THE FASTEST GROWTH IN BIOTECHS NEXL NEXELL THE FASTEST GROWTH IN BIOTECHS NEXL
CUSIP: 30161Q104